Pro Medicus (PMCUF) Stock Price, News & Analysis

Company Overview

Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Key Stats

• Today's Range: $121.00 to $121.00
• 50-Day Range: $80.09 to $123.50
• 52-Week Range: $51.07 to $123.50
• Volume: 500 shs
• Average Volume: 552 shs
• Market Capitalization: N/A
• P/E Ratio: 8,066.67
• Dividend Yield: 0.02%
• Price Target: N/A
• Consensus Rating: N/A

Pro Medicus Stock Analysis - MarketRank™

Pro Medicus scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pro Medicus.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pro Medicus is 8,066.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 119.71.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pro Medicus is 8,066.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 109.21.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Pro Medicus has a short interest ratio ("days to cover") of 2285.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Pro Medicus has recently increased by 1.62%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Pro Medicus pays a meaningful dividend of 1.63%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Pro Medicus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Pro Medicus is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Pro Medicus has a short interest ratio ("days to cover") of 2285.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Pro Medicus has recently increased by 1.62%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.38

News Sentiment

Pro Medicus has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pro Medicus this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pro Medicus insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 10.84% of the stock of Pro Medicus is held by institutions.

PMCUF Stock Analysis - Frequently Asked Questions

How have PMCUF shares performed this year?

Pro Medicus' stock was trading at $64.75 at the beginning of the year. Since then, PMCUF shares have increased by 86.9% and is now trading at $121.00.
View the best growth stocks for 2024 here.

How do I buy shares of Pro Medicus?

Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PMCUF
• CUSIP: N/A
• CIK: N/A
• Web: www.promed.com.au
• Phone: 61 3 9429 8800
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 8,066.67
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A